Enterprise League logo
Nuovo Biologics, LLC Logo

Nuovo Biologics, LLC

Miami, United States (US) · Health and Medical

Do your work at Nuovo Biologics, LLC?

Claim this profile to manage your company.

Verified by Enterprise League

Data quality

Complete · Accuracy

Last verified

May 2026

#drug and biologics development

#clinical research

#clinical trials

#peptide chemistry

#antiviral product research

#translational research

#contract manufacturing

#regulatory compliance

#oncology product development

Nuovo Biologics, LLC is a Health and Medical company based in Miami, United States (US), founded in 2010, with 2-10 employees. Nuovo Biologics, LLC's profile is verified on Enterprise League.

Overview

CYGNOS BioTech, LLC is a South Florida-based biotechnology company dedicated to pioneering innovative biologic, antiviral, and oncology therapeutics. Established in 2023 from the legacy of Nuovo Biologics, LLC, we operate under a ‘One Health’ paradigm, recognizing the interconnectedness of animal and human health. Our mission is to develop safe and efficacious drugs and biologicals that maximize the well-being of both animal and human populations.

Leveraging a translational research model, we focus initially on animal health, specifically designing a pathway for rapid development and commercialization of therapeutics directly applicable to human infectious disease markets. CYGNOS BioTech’s core expertise lies in peptide chemistry, antiviral drug development, and oncology research, supported by a strong network of collaborators and a commitment to regulatory compliance. With a proven track record of innovation and a strategic approach to drug development, CYGNOS BioTech is poised to make a significant impact on global health.
Visit Official Website

Most teams do this before shortlisting

Contact Details

info@cygnosbiotech.com

Miami, United States (US), P.O. Box 160471

+1

Founded

2010

Company Type

Private Limited Company

Employees

2-10

Categories

Biopharma
Life Science
Biotechnology

Keywords

#drug and biologics development

#clinical research

#clinical trials

#peptide chemistry

#antiviral product research

#translational research

#contract manufacturing

#regulatory compliance

#oncology product development

Awards

• 2026 OpenSee all

Products

Default Product Image
MMX
Biotechnology

MMX is an investigational new drug formulation developed by CYGNOS BioTech for the treatment of oral canine malignant melanoma stages II & III. In vitro studies have shown that MMX inhibits cell proliferation in melanoma cells, and in vivo studies have demonstrated significant tumor reduction in affected canines. This represents a promising therapeutic approach for a prevalent and challenging cancer in dogs.

N/A

Default Product Image
PVX
Biotechnology

PVX is a novel peptide therapeutic developed by CYGNOS BioTech for the treatment of viral infections in non-food animals, including dogs, cats, horses, and birds. In vitro and pilot animal studies demonstrate significant antiviral activity across a broad spectrum of virus families. This proprietary technology is protected by eleven issued patents and has received an Investigational New Animal Drug (INAD) number from the FDA.

N/A

Companies teams usually look at after Nuovo Biologics, LLC

Comparing a few options usually leads to better decisions

  • Save companies to compare later. Useful when sharing options with your team

This is how your company profile looks to others.